A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

Trial Profile

A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2014

At a glance

  • Drugs Trevogrumab (Primary) ; Trevogrumab (Primary)
  • Indications Muscular atrophy
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 12 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top